Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 1:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 369 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Daiichi Sankyo Clear all
Completed No phase listed Observational

IMPROVE Stroke Care- Developing and Optimizing Regional Systems of Stroke Care

NCT04242784
View directory record Official record
Conditions
Acute Stroke, Intracranial Hemorrhages, Subarachnoid Hemorrhage
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
21,646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Asheville, North Carolina • Charlotte, North Carolina • Concord, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Jul 24, 2026, 1:55 AM EDT
Completed Phase 1 Interventional

DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis

NCT03305471
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
DS-2330b PIB, Placebo, Sevelamer, DS-2330b Tablet
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2019 · Synced Jul 24, 2026, 1:55 AM EDT
Completed Phase 1 Interventional

Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors

NCT01364844
View directory record Official record
Conditions
Solid Tumor, Colorectal Cancer, Endometrial Cancer
Interventions
DS-7423
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Detroit, Michigan • New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 24, 2014 · Synced Jul 24, 2026, 1:55 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT06161025
View directory record Official record
Conditions
Solid Cancer
Interventions
R-DXd, Paclitaxel, Topotecan, PLD
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
43
States / cities
Anchorage, Alaska • New Haven, Connecticut • Coral Gables, Florida + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 24, 2026, 1:55 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

NCT04538742
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Trastuzumab deruxtecan, Durvalumab, Paclitaxel, Pertuzumab, Tucatinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
10
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Commack, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Jul 24, 2026, 1:55 AM EDT
Completed Phase 1 Interventional

Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis

NCT01878123
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
AMP-110, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Anniston, Alabama • Duncansville, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Jul 24, 2026, 1:55 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Food Effects on Milademetan Pharmacokinetics in Healthy Participants

NCT03647202
View directory record Official record
Conditions
Food Effects on Pharmacokinetics
Interventions
Milademetan Treatment A, Milademetan Treatment B, Milademetan Treatment C
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Jul 24, 2026, 1:55 AM EDT
Completed Phase 2 Interventional Results available

Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

NCT04644237
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Trastuzumab deruxtecan
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
Aurora, Colorado • Orlando, Florida • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Jul 24, 2026, 1:55 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment

NCT06740799
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Quizartinib
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
Miami, Florida • St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 24, 2026, 1:55 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma

NCT01349036
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
PLX3397
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Jul 24, 2026, 1:55 AM EDT
Completed No phase listed Observational

Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer

NCT06040593
View directory record Official record
Conditions
Hormone-receptor-positive Breast Cancer, HER2-low Breast Cancer, HER2-negative Breast Cancer
Interventions
No drug
Other
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
927 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 25, 2024 · Synced Jul 24, 2026, 1:55 AM EDT
Recruiting Phase 2 Interventional

TRUDI: TDXD+Durva in HER2+/Low IBC

NCT05795101
View directory record Official record
Conditions
Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2-positive Breast Cancer, HER2 Low Breast Adenocarcinoma, Breast Cancer
Interventions
Trastuzumab deruxtecan, Durvalumab
Drug
Lead sponsor
Filipa Lynce, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
3
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Jul 24, 2026, 1:55 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of DS-7011a in Patients With Systemic Lupus Erythematosus

NCT05638802
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
DS-7011a, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Anniston, Alabama • North Little Rock, Arkansas • North Miami Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jul 24, 2026, 1:55 AM EDT
Completed Phase 1 Interventional

A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT01390337
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
AC220, daunorubicin, cytarabine
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
5
States / cities
Jacksonville, Florida • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Jul 24, 2026, 1:55 AM EDT
Completed Phase 2 Interventional Results available

Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer

NCT04744831
View directory record Official record
Conditions
Advanced Colorectal Cancer
Interventions
DS-8201a 5.4 mg/kg Q3W, DS-8201a 6.4 mg/kg Q3W
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Chicago, Illinois • Louisville, Kentucky • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Jul 24, 2026, 1:55 AM EDT
Not listed Phase 4 Interventional

A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure

NCT03088072
View directory record Official record
Conditions
Non-Valvular Atrial Fibrillation, Left Atrial Appendage Closure
Interventions
Edoxaban, WATCHMAN LAA Closure, Aspirin and Clopidogrel, Aspirin and Warfarin
Drug · Device
Lead sponsor
Scripps Health
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Jul 24, 2026, 1:55 AM EDT
Recruiting Phase 3 Interventional

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT06350097
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Osimertinib, Datopotamab Deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
36
States / cities
Fountain Valley, California • Los Alamitos, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 24, 2026, 1:55 AM EDT
Completed Phase 2 Interventional

Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer

NCT00004060
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
exatecan mesylate
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2012 · Synced Jul 24, 2026, 1:55 AM EDT
Recruiting Phase 2 Interventional

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

NCT04379596
View directory record Official record
Conditions
Gastric Cancer
Interventions
Fluorouracil (5-FU), Capecitabine, Durvalumab, Oxaliplatin, Trastuzumab, Trastuzumab deruxtecan, Cisplatin, Pembrolizumab, Volrustomig, Rilvegostomig
Drug · Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
10
States / cities
Santa Monica, California • Westwood, Kansas • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 24, 2026, 1:55 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

NCT05374512
View directory record Official record
Conditions
Breast Cancer
Interventions
Dato-DXd, Paclitaxel, Nab-paclitaxel, Carboplatin, Capecitabine, Eribulin mesylate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
27
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 24, 2026, 1:55 AM EDT
Completed Phase 1 Interventional Results available

Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors

NCT01525602
View directory record Official record
Conditions
Solid Tumors
Interventions
PLX3397, Paclitaxel
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
8
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Jul 24, 2026, 1:55 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

NCT05629585
View directory record Official record
Conditions
Breast Cancer
Interventions
Dato-DXd, Durvalumab, Capecitabine, Pembrolizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
88
States / cities
Gilbert, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 70 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 24, 2026, 1:55 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Colesevelam Hydrogen Chloride (HCl) Powder For Oral Suspension Versus Generic Cholestyramine Through Use of the Bile Acid Sequestrant Acceptability (BASA) Scale

NCT01122108
View directory record Official record
Conditions
Healthy
Interventions
Cholestyramine, Colesevelam HCl
Drug
Lead sponsor
Louisville Metabolic and Atherosclerosis Research Center
Other
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 6, 2010 · Synced Jul 24, 2026, 1:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers

NCT04019652
View directory record Official record
Conditions
Hypertension, Mineralocorticoid Receptor Antagonist
Interventions
CS-3150, Moxifloxacin, Placebo matching moxifloxacin tablet, Placebo matching CS-3150
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 45 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2019 · Synced Jul 24, 2026, 1:55 AM EDT